Boston Beer Company (SAM), based in Boston, MA, is facing a significant decline in demand as alcohol consumption trends shift in the United States. A recent Gallup poll indicates that only about 54% of Americans drink alcohol, a decrease of 8% over the past three years. This shift is exacerbated by the impact of GLP-1 weight loss drugs, which are reportedly reducing alcohol intake by affecting brain reward pathways.
The company has seen a decline in its annual earnings per share since 2022 and anticipates negative revenue growth through 2027. Key brands, including Twisted Tea and Truly, are losing market share, while over a third of consumers are reducing their alcohol purchases due to higher prices and the growing popularity of alternatives such as cannabis. Simultaneously, tariff costs are expected to climb to $20-$30 million by 2026, further complicating Boston Beer’s efforts to improve profit margins.
Despite significant underperformance, SAM shares still carry a P/E ratio of 20.42x, higher than the Beverage-Alcohol Industry average of 14.08x, indicating that the company may remain overvalued amidst its challenges.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
